About Aldeyra Therapeutics

Aldeyra’s Mission

At Aldeyra, we are devoted to developing medications to enhance the well-being of patients dealing with immune-mediated and metabolic illnesses. Our portfolio of product candidates are designed to target the inhibition of inflammatory cells associated with both ocular and systemic ailments, filling the gaps left by existing treatments. Through multiple ongoing clinical trials, our singular objective is to empower patients in achieving healthier and more fulfilling lives.

Gloved hand holding a slide next to a microscope

We have developed a novel pharmaceutical platform that targets a group of harmful endogenous molecules called RASP (reactive aldehyde species). RASP are associated with various inflammatory, metabolic, and neurodegenerative conditions.

At Aldeyra, we’re committed to advancing therapies that make a real difference in patients’ lives, and we look forward to sharing more about our progress and achievements with you.

Currently, we’re advancing the development of other novel RASP modulators to treat RASP-associated diseases. Our variety of small molecules are designed to bind and facilitate the degradation of RASP, thereby preventing RASP-associated inflammation and toxicity. Our flagship product candidate, reproxalap, has demonstrated rapid and broad-based activity in treating dry eye disease, with a consistent safety profile observed across multiple late-stage clinical trials.

In laboratory studies, reproxalap has been observed to effectively trap and degrade RASP, without directly affecting receptors, enzymes, ions channels, or other proteins. Drug-RASP adducts are rapidly broken down within cellular environments, leading to undetectable levels of both reproxalap and RASP.

By forming covalent drug-RASP adducts that undergo degradation, our RASP modulators have the potential to treat disease by reducing RASP levels.